Linden Thomas Advisory Services LLC Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Linden Thomas Advisory Services LLC grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,920 shares of the medical equipment provider’s stock after buying an additional 517 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Intuitive Surgical were worth $1,997,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Baystate Wealth Management LLC lifted its stake in shares of Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC lifted its stake in shares of Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the last quarter. Atticus Wealth Management LLC lifted its stake in shares of Intuitive Surgical by 85.4% during the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 41 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Intuitive Surgical during the 3rd quarter worth $25,000. Finally, Headinvest LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter worth $28,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ISRG shares. Robert W. Baird decreased their price objective on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday. BTIG Research upped their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday. Piper Sandler upped their target price on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup upped their target price on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Truist Financial upped their target price on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $370.20, for a total transaction of $740,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at $9,373,093.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the transaction, the vice president now owns 110 shares in the company, valued at $43,677.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the transaction, the director now owns 25,319 shares in the company, valued at approximately $9,373,093.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 248,418 shares of company stock worth $95,927,097. 0.80% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded up $7.75 during midday trading on Tuesday, hitting $376.68. 1,071,456 shares of the company were exchanged, compared to its average volume of 1,666,347. The firm has a market capitalization of $133.51 billion, a PE ratio of 68.22, a price-to-earnings-growth ratio of 5.69 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The business has a fifty day simple moving average of $386.57 and a two-hundred day simple moving average of $344.41.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $1.00 earnings per share. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.